Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification
(2018) In Oncotarget 9(5). p.6188-6200- Abstract
Periampullary adenocarcinoma, including pancreatic cancer, is a heterogeneous group of tumors with dismal prognosis, partially due to lack of reliable targetable and predictive biomarkers. RNA-binding motif protein 3 (RBM3) has previously been shown to be an independent prognostic and predictive biomarker in several types of cancer. Herein, we examined the prognostic value of RBM3 in periampullary adenocarcinoma, as well as the effects following RBM3 suppression in pancreatic cancer cells in vitro. RBM3 mRNA levels were examined in 176 pancreatic cancer patients from The Cancer Genome Atlas. Immunohistochemical expression of RBM3 was analyzed in tissue microarrays with primary tumors and paired lymph node metastases from 175 consecutive... (More)
Periampullary adenocarcinoma, including pancreatic cancer, is a heterogeneous group of tumors with dismal prognosis, partially due to lack of reliable targetable and predictive biomarkers. RNA-binding motif protein 3 (RBM3) has previously been shown to be an independent prognostic and predictive biomarker in several types of cancer. Herein, we examined the prognostic value of RBM3 in periampullary adenocarcinoma, as well as the effects following RBM3 suppression in pancreatic cancer cells in vitro. RBM3 mRNA levels were examined in 176 pancreatic cancer patients from The Cancer Genome Atlas. Immunohistochemical expression of RBM3 was analyzed in tissue microarrays with primary tumors and paired lymph node metastases from 175 consecutive patients with resected periampullary adenocarcinoma. Pancreatic cancer cells were transfected with anti-RBM3 siRNA in vitro and the influence on cell viability following chemotherapy, transwell migration and invasion was assessed. The results demonstrated that high mRNA-levels of RBM3 were significantly associated with a reduced overall survival (p = 0.026). RBM3 protein expression was significantly higher in lymph node metastases than in primary tumors (p = 0.005). High RBM3 protein expression was an independent predictive factor for the effect of adjuvant chemotherapy and an independent negative prognostic factor in untreated patients (p for interaction = 0.003). After siRNA suppression of RBM3 in vitro, pancreatic cancer cells displayed reduced migration and invasion compared to control, as well as a significantly increased resistance to chemotherapy. In conclusion, the strong indication of a positive response predictive effect of RBM3 expression in pancreatic cancer may be highly relevant in the clinical setting and merits further validation.
(Less)
- author
- Karnevi, Emelie
LU
; Dror, Liv Ben
LU
; Mardinoglu, Adil
; Elebro, Jacob
LU
; Heby, Margareta
LU
; Olofsson, Sven Erik
LU
; Nodin, Björn
LU
; Eberhard, Jakob
LU
; Gallagher, William
; Uhlén, Mathias
and Jirström, Karin
LU
(Less) - organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Pancreatic cancer, Periampullary cancer, Prediction, Prognosis, RBM3
- in
- Oncotarget
- volume
- 9
- issue
- 5
- pages
- 13 pages
- publisher
- Impact Journals
- external identifiers
-
- pmid:29464064
- scopus:85040697313
- ISSN
- 1949-2553
- DOI
- 10.18632/oncotarget.23486
- language
- English
- LU publication?
- yes
- id
- 5c3ea6ec-fb9b-4569-9173-7627ce441fbc
- date added to LUP
- 2018-02-05 11:18:53
- date last changed
- 2024-02-13 15:04:20
@article{5c3ea6ec-fb9b-4569-9173-7627ce441fbc,
abstract = {{<p>Periampullary adenocarcinoma, including pancreatic cancer, is a heterogeneous group of tumors with dismal prognosis, partially due to lack of reliable targetable and predictive biomarkers. RNA-binding motif protein 3 (RBM3) has previously been shown to be an independent prognostic and predictive biomarker in several types of cancer. Herein, we examined the prognostic value of RBM3 in periampullary adenocarcinoma, as well as the effects following RBM3 suppression in pancreatic cancer cells in vitro. RBM3 mRNA levels were examined in 176 pancreatic cancer patients from The Cancer Genome Atlas. Immunohistochemical expression of RBM3 was analyzed in tissue microarrays with primary tumors and paired lymph node metastases from 175 consecutive patients with resected periampullary adenocarcinoma. Pancreatic cancer cells were transfected with anti-RBM3 siRNA in vitro and the influence on cell viability following chemotherapy, transwell migration and invasion was assessed. The results demonstrated that high mRNA-levels of RBM3 were significantly associated with a reduced overall survival (p = 0.026). RBM3 protein expression was significantly higher in lymph node metastases than in primary tumors (p = 0.005). High RBM3 protein expression was an independent predictive factor for the effect of adjuvant chemotherapy and an independent negative prognostic factor in untreated patients (p for interaction = 0.003). After siRNA suppression of RBM3 in vitro, pancreatic cancer cells displayed reduced migration and invasion compared to control, as well as a significantly increased resistance to chemotherapy. In conclusion, the strong indication of a positive response predictive effect of RBM3 expression in pancreatic cancer may be highly relevant in the clinical setting and merits further validation.</p>}},
author = {{Karnevi, Emelie and Dror, Liv Ben and Mardinoglu, Adil and Elebro, Jacob and Heby, Margareta and Olofsson, Sven Erik and Nodin, Björn and Eberhard, Jakob and Gallagher, William and Uhlén, Mathias and Jirström, Karin}},
issn = {{1949-2553}},
keywords = {{Pancreatic cancer; Periampullary cancer; Prediction; Prognosis; RBM3}},
language = {{eng}},
number = {{5}},
pages = {{6188--6200}},
publisher = {{Impact Journals}},
series = {{Oncotarget}},
title = {{Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification}},
url = {{http://dx.doi.org/10.18632/oncotarget.23486}},
doi = {{10.18632/oncotarget.23486}},
volume = {{9}},
year = {{2018}},
}